Editas Medicine Files 8-K on Financials
Ticker: EDIT · Form: 8-K · Filed: May 8, 2024 · CIK: 1650664
Sentiment: neutral
Topics: financials, sec-filing
Related Tickers: EDAS
TL;DR
EDAS filed an 8-K detailing financials - check for updates.
AI Summary
Editas Medicine, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, incorporated in Delaware, is based in Cambridge, MA, and operates in the biological products sector.
Why It Matters
This filing provides crucial updates on Editas Medicine's financial health and operational status, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant risk disclosures.
Key Players & Entities
- Editas Medicine, Inc. (company) — Registrant
- May 8, 2024 (date) — Date of Report
- Cambridge, Massachusetts (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on Editas Medicine's results of operations and financial condition, along with financial statements and exhibits.
When was this 8-K filing submitted?
The filing was submitted on May 8, 2024.
Where is Editas Medicine, Inc. headquartered?
Editas Medicine, Inc.'s principal executive offices are located at 11 Hurley Street, Cambridge, Massachusetts.
What is Editas Medicine's fiscal year end?
Editas Medicine's fiscal year ends on December 31st.
What industry sector does Editas Medicine operate in?
Editas Medicine operates in the Biological Products (No Diagnostic Substances) sector.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-05-08 07:08:48
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto
Filing Documents
- edit-20240508.htm (8-K) — 26KB
- editasmedicinepressrelease.htm (EX-99.1) — 63KB
- image_0.jpg (GRAPHIC) — 60KB
- 0001650664-24-000034.txt ( ) — 303KB
- edit-20240508.xsd (EX-101.SCH) — 2KB
- edit-20240508_lab.xml (EX-101.LAB) — 21KB
- edit-20240508_pre.xml (EX-101.PRE) — 12KB
- edit-20240508_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 8, 2024, Editas Medicine, Inc. (the "Company") issued a press release announcing financial results for the fiscal quarter ended March 31, 2024 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "Filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on May 8, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: May 8, 2024 By: /s/ Erick Lucera Erick Lucera Chief Financial Officer